Could a common diabetes pill ease long COVID?
NCT ID NCT06907251
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This Phase 3 trial tests whether dapagliflozin, a drug used for diabetes, can improve quality of life in people with long COVID. 192 adults with persistent symptoms for at least 12 weeks after a COVID infection will receive either the drug or a placebo daily for 12 months. The main goal is to see if the drug helps with overall well-being and reduces complications like diabetes or heart problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dapagliflozin (a diabetes drug taken as a pill once daily)
- What this could lead to
- If it works, this could offer a simple, daily pill to help manage long COVID symptoms and improve quality of life.
- What could go wrong
- This is a relatively small Phase 3 trial. Dapagliflozin is a diabetes drug, and its benefits for long COVID are unproven. It may not work for everyone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?